Communication

Actualités

Turenne Santé acquires ABL Lyon, creating Active Biomarkers

5 novembre 2020
Actualités

Lyon, 5 November 2020 – ABL Lyon, a subsidiary of Institut Mérieux and a benchmark laboratory in biomarker analysis, is acquired by Turenne Santé via its private equity fund Capital Santé 2. Alongside its general manager, Marc Essodaigui, and the management team, Turenne Santé is positioning itself as majority shareholder in order to provide the company with significant resources to finance an ambitious development plan. ABL Lyon has been renamed Active Biomarkers. En savoir plus